View in EDS HTML Full Text PDF Full Text

A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC.

Saved in:
Bibliographic Details
Title: A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC.
Authors: Wang, Yuanyuan1,2,3 (AUTHOR), Guo, Haoyue1,2,3 (AUTHOR), Han, Ruoshuang3,4 (AUTHOR), Wu, Yuhan3,5 (AUTHOR), He, Taiping1,2,3 (AUTHOR), Diao, Meng1,2,3 (AUTHOR), Xiong, Anwen1,2,3 (AUTHOR), Zhou, Fei1,2,3 (AUTHOR), Cheng, Lei6 (AUTHOR), Zhao, Chao6 (AUTHOR), Li, Xuefei6 (AUTHOR), Zhou, Caicun1,2,3 (AUTHOR) doctorcaicunzhou@163.com
Source: Cellular Oncology (2211-3428). Feb2026, Vol. 49 Issue 1, p1-13. 13p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:22113428
DOI:10.1007/s13402-025-01152-8